Cancer of the Prostate Clinical Trial
Official title:
Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer
The main aim of this trial is to assess the response rate, the feasibility and toxicity of the treatment with antigen loaded Dendritic Cell Vaccination in Prostate Cancer patients. Furthermore we want to investigate biological responses by measuring markers of in-vivo and ex-vivo immunomodulation.
Dendritic cell (DC)-based immunotherapy is a promising approach to augment tumor antigen-specific T cell responses in cancer patients. However, tumor escape with down-regulation or complete loss of target antigens may limit the susceptibility of tumor cells to the immune attack. Concomitant generation of T cell responses against several immunodominant antigens may circumvent this potential drawback. In this phase I/II clinical trial, the investigators determined the immunostimulatory capacity of autologous DC pulsed with multiple T cell epitopes derived from four different prostate-specific antigens in patients with advanced hormone-refractory prostate cancer. Autologous DC of HLA-A*0201-positive patients are loaded with antigenic peptides derived from prostate stem cell antigen, prostatic acid phosphatase, prostate-specific membrane antigen, and prostate-specific antigen. A strict quality control concerning the expression of surface markers and the migratory capacity of the DC secured optimal stimulatory capacity. DC were applied intradermally six times at biweekly intervals followed by monthly booster injections. Tolerability and PSA response will be investigated. Antigen-specific immune responses will be quantified. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03653819 -
High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs
|
N/A | |
| Withdrawn |
NCT05191017 -
Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC
|
Phase 1/Phase 2 | |
| Completed |
NCT00970203 -
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06363266 -
A SMART Design to Optimize the Delivery of TEMPO for Men With Prostate Cancer and Their Caregivers
|
N/A | |
| Active, not recruiting |
NCT02003924 -
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
|
Phase 3 | |
| Completed |
NCT00643617 -
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
|
N/A | |
| Completed |
NCT00844792 -
Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
| Completed |
NCT01303705 -
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
|
Phase 1 | |
| Completed |
NCT02578940 -
Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer
|
Phase 3 | |
| Completed |
NCT04057859 -
PCa Patients Managed With ADT to Examine the Effect of Nutritional Guidance and Aerobic/Resistance Fitness Training
|
||
| Completed |
NCT00564928 -
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer
|
Phase 2 | |
| Completed |
NCT02958787 -
Vessel Sparing Prostate Radiation Therapy
|
Phase 2 | |
| Recruiting |
NCT05241236 -
MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer
|
||
| Active, not recruiting |
NCT03939689 -
Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone
|
Phase 2 | |
| Completed |
NCT02274350 -
The Herlev Hospital Post Radiation Therapy for Localized Prostate Cancer Database for Sexual Side Effects
|
N/A | |
| Completed |
NCT00744549 -
Study of Antioxidants on MRI Detectable Early Stage Prostate Cancer Among Men on Active Surveillance
|
Phase 2 | |
| Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02212548 -
Prostate-Rectal Separation With PEG Hydrogel and Its Effect on Decreasing Rectal Dose
|
N/A | |
| Completed |
NCT04017325 -
European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow-up
|
||
| Active, not recruiting |
NCT03238170 -
MR-simulation in Radiotherapy for Prostate Cancer
|
N/A |